Merrimack Pharmaceuticals (MACK) Earns News Sentiment Rating of 0.10
Media stories about Merrimack Pharmaceuticals (NASDAQ:MACK) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.9617230435549 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- $33.00 Million in Sales Expected for Merrimack Pharmaceuticals, Inc. (MACK) This Quarter (americanbankingnews.com)
- Form 8-K MERRIMACK PHARMACEUTICAL For: Nov 26 – StreetInsider.com (streetinsider.com)
- Merrimack Announces Appointment of George Demetri, M.D., to … – PR Newswire (press release) (prnewswire.com)
- Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors (finance.yahoo.com)
- Merrimack Pharmaceuticals, Inc. (MACK) Expected to Post Earnings of -$0.28 Per Share (americanbankingnews.com)
Several research analysts have recently weighed in on MACK shares. ValuEngine raised shares of Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Zacks Investment Research cut Merrimack Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Robert W. Baird reissued a “hold” rating and issued a $15.00 target price on shares of Merrimack Pharmaceuticals in a research note on Friday, October 13th.
In other news, Director Ulrik B. Nielsen sold 14,756 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $14.46, for a total transaction of $213,371.76. Following the transaction, the director now directly owns 37,437 shares of the company’s stock, valued at $541,339.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ulrik B. Nielsen sold 21,556 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $14.40, for a total value of $310,406.40. Following the transaction, the director now directly owns 37,437 shares in the company, valued at $539,092.80. The disclosure for this sale can be found here. In the last three months, insiders sold 44,308 shares of company stock worth $637,558. 8.53% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/04/merrimack-pharmaceuticals-mack-earns-news-sentiment-rating-of-0-10.html.
About Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Stock Ratings for Merrimack Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.